EP1425294B2 - Analyse zirkulierender tumorzellen, fragmente und trümmer - Google Patents

Analyse zirkulierender tumorzellen, fragmente und trümmer Download PDF

Info

Publication number
EP1425294B2
EP1425294B2 EP02761478A EP02761478A EP1425294B2 EP 1425294 B2 EP1425294 B2 EP 1425294B2 EP 02761478 A EP02761478 A EP 02761478A EP 02761478 A EP02761478 A EP 02761478A EP 1425294 B2 EP1425294 B2 EP 1425294B2
Authority
EP
European Patent Office
Prior art keywords
cells
ctc
analysis
cell
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP02761478A
Other languages
English (en)
French (fr)
Other versions
EP1425294A4 (de
EP1425294B1 (de
EP1425294A2 (de
Inventor
Galla Chandra Rao
Christopher Larson
Madeline Repollet
Herman Rutner
Leon Terstappen
Shawn Mark O'hara
Steven Gross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Diagnostics LLC
Original Assignee
Veridex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26979228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1425294(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Veridex LLC filed Critical Veridex LLC
Publication of EP1425294A2 publication Critical patent/EP1425294A2/de
Publication of EP1425294A4 publication Critical patent/EP1425294A4/de
Application granted granted Critical
Publication of EP1425294B1 publication Critical patent/EP1425294B1/de
Publication of EP1425294B2 publication Critical patent/EP1425294B2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/549—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic with antigen or antibody entrapped within the carrier
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Definitions

  • CTC circulating tumor cells
  • the presence of tumor cells in the circulation can be used to screen for cancer in place of, or in conjunction with, other tests, such as mammography for breast cancer, or measurements of Prostate Specific Antigen (PSA) for prostate cancer.
  • PSA Prostate Specific Antigen
  • the organ origin of such cells may readily be determined, e.g., breast, prostate, colon, lung, ovarian or other non-hematopoietic cancers.
  • Malignant tumors are characterized by their ability to invade adjacent tissue.
  • tumors with a diameter of 1mm are vascularized and animal studies show that as much as 4% of the cells present in the tumor can be shed into the circulation in a 24 hour period ( Butler, TP & Gullino PM, 1975 Cancer Research 35:512-516 ).
  • the shedding capacity of a tumor is most likely dependent on the aggressiveness of the tumor.
  • tumor cells are shed into the circulation on a continuous basis, it is believed that none or only a small fraction will give rise to distant metastasis (Butler & Gullino, supra ) .
  • Increase in tumor mass might be expected to be proportional to an increase in the frequency of CTC, as single cells, or clusters of cells with increased adhesiveness (and possibly greater invasive potential). If this were found to be the case, methods available with a high level of sensitivity would facilitate assessment of tumor load in patients with distant metastasis as well as those with localized disease. Detection of tumor cells in peripheral blood of patients with localized disease has the potential not only to detect a tumor at an earlier stage but also to provide indications as to the potential invasiveness of the tumor.
  • whole blood is a complex body fluid containing diverse populations of cellular and soluble components capable of undergoing numerous biochemical and enzymatic reactions in vivo and in vitro, particularly on prolonged storage for more than 24hrs. Some of these reactions are related to immunological destruction of CTC that are recognized as foreign species.
  • the patient's immune response weakens or destroys tumor cells by the normal defense mechanisms including phagocytosis and neutrophil activation.
  • Chemotherapy similarly is intended to reduce both cell function and proliferation by inducing cell death by necrosis. Besides these external destructive factors, tumor cells damaged in a hostile environment may undergo programmed death or apoptosis.
  • Normal and abnormal cells including CTC undergoing apoptosis or necrosis, have altered membrane permeabilities that allow escape of DNA, RNA, and other intracellular components leading to formation of damaged cells, fragmented cells, cellular debris, and eventual complete disintegration.
  • tumor cell debris may still bear epitopes or determinants characteristic of intact cells and can lead to spurious increases in the number of detected circulating cancer cells.
  • Whole blood specimens from healthy individuals also have been observed to undergo destruction of labile blood cell components, herein categorized as decreased blood quality, on prolonged storage for periods of greater than 24 hours. For example, erythrocytes may rupture and release hemoglobin and produce cell ghosts.
  • Leukocytes particularly granulocytes, are known to be labile and diminish on storage.
  • Such changes increase the amount of cellular debris that can interfere with the isolation and detection of rare target cells such as CTC.
  • the combined effects of these destructive processes can substantially increase cellular debris, which is readily detectable, for instance, in flow cytometric and microscopic analyses, such as CellSpotter® or CellTracks TM .
  • Detection of circulating tumor cells by microscopic imaging is similarly adversely affected by spurious decreases in classifiable tumor cells and a corresponding increase in interfering stainable debris.
  • maintaining the integrity or the quality of the blood specimen is of utmost importance, since there may be a delay of as much as 24 hours between blood draw and specimen processing.
  • Such delays are to be expected, since the techniques and equipment used in processing blood for this assay may not be readily available in every laboratory.
  • the time necessary for a sample to arrive at a laboratory for sample processing may vary considerably. It is therefore important to establish the time window within which a sample can be processed. In routine hematology analyses, blood samples can be analyzed within 24 hours.
  • the time window in which a blood sample can be analyzed is shorter.
  • An example is immunophenotyping of blood cells, which, in general, must be performed within 24 hours.
  • larger volumes of blood have to be processed, and in vitro degradation of the blood sample can become more problematic as materials released by disintegrating cells, both from CTC and from hematopoietic cells, can increase the background and therefore decrease the ability to detect tumor cells.
  • CTC can be considered immunologically foreign species, normal cellular immune responses of the host will occur in vivo even before blood draw. Also large numbers of CTC can be continuously shed from a tumor site, and a steady-state level is maintained in which destruction of CTC equals the shedding rate which in turn depends on the size of the tumor burden (see JG Moreno et al. "Changes in Circulating Carcinoma Cells in Patients with Metastatic Prostate Cancer Correlates with Disease State.” Urology 58. 2001 ).
  • Chen describes the use of an adhesion matrix for enumerating tumor cells. Briefly, the matrix is coated with specific adhesion molecules that will bind viable cancer cells with presumed metastatic potential. The matrix can then be analyzed for the presence and type of captured cells. Also described are methods for using the matrix in screening treatments. While steps are taken to discriminate between intact cells and apoptotic or necrotic cells, the apoptotic or necrotic cells are specifically excluded from analysis.
  • WO00/47998 from Cell Works, two pathways are described for CTC, terminal and proliferative. Both pathways begin with an "indeterminate" cell that progresses, as determined by morphological differences, down either the terminal or proliferative pathway. A cell in the terminal pathway eventually is destroyed, and a cell in the proliferative pathway will form a new metastatic colony as a metastatic tumor. This proliferative pathway (cells and clusters) is the focus as a potential diagnostic, but minimizes the significance of cell fragments or debris. These two pathways were designed to explain morphological differences seen in patient samples.
  • Apoptosis is characterized by a series of stepwise slow intracellular events, which differs from necrosis or rapid cell death triggered or mediated by an extracellular species, e.g. a cytotoxic anti-tumor drug.
  • CTC can circulate as both live and dead cells, wherein "dead” comprises the full range of damaged and fragmented cells as well as CTC-derived debris.
  • the tumor burden is probably best represented by the total of both intact CTC, including clusters, and damaged CTC, which bear morphological characteristics of cells, but are distinct from clumps and/or aggregates.
  • CTC debris that is positively stained for cytokeratin may also have densities falling in the RBC or higher ranges, since most intracellular components (with the possible exception of lipophilic membrane fragments that may be located near the plasma-buffy coat interface) have densities in the range of 1.15 to 1.3. Hence, a substantial portion of damaged CTC and CTC debris may be located outside the buffy coat layer, and would not be seen by the density gradient methods, such as those in WO00/47998 . Some images of damaged or fragmented CTC are shown, but it is quite possible the damage occurred during cytospin or subsequent processing, and is thus artifactual. While the densities of most intact tumor cells may fall in the WBC region, it is quite likely that damaged CTC in patient samples have higher densities that may place them in the RBC layer; outside the reach of gradient techniques.
  • Epithelial cells in their tissue of origin obey established growth and development "rules". Those rules include population control. This means that under normal circumstances the number and size of the cells remains constant and changes only when necessary for normal growth and development of the organism. Only the basal cells of the epithelium or immortal cells will divide and they will do so when it is necessary for the epithelium to perform its function, whatever it is depending in the nature and location of the epithelium. Under some abnormal but benign circumstances, cells will proliferate and the basal layer will divide more than usual, causing hyperplasia. Under some other abnormal but benign circumstances, cells may increase in size beyond what is normal for the particular tissue, causing cell gigantism, as in folic acid deficiency.
  • Epithelial tissue may increase in size or number of cells also due to pre-malignant or malignant lesions. In these cases, changes similar to those described above are accompanied by nuclear abnormalities ranging from mild in low-grade intraepithelial lesions to severe in malignancies. It is believed that changes in these cells may affect portions of the thickness of the epithelium and as they increase in severity will comprise a thicker portion of such epithelium. These cells do not obey restrictions of contact inhibition and continue growing without tissue controls. When the entire thickness of the epithelium is affected by malignant changes, the condition is recognized as a carcinoma in situ (CIS).
  • CIS carcinoma in situ
  • the malignant cells eventually are able to pass through the basement membrane and invade the stroma of the organ as their malignant potential increases. After invading the stroma, these cells are believed to have the potential for reaching the blood vessels. Once they infiltrate the blood vessels, cells find themselves in a completely different environment from the one they originated from.
  • the cells may infiltrate the blood vessels as single cells or as clusters of two or more cells.
  • a single cell of epithelial origin circulating through the circulatory system is destined to have one of two outcomes. It may die or it may survive.
  • Single Cells :
  • a decrease in the number of tumor cells and/ or increase in the response index may represent a response to patient therapy.
  • a low response index may indicate that the patient is not responding to the treatment and or that the pt's immune system is not able to handle the tumor load.
  • CellSpotter® can be used to help in the decision tree of these patients. All patients with an abnormal pap (5-10% of the pap smears in the USA) can immediately be tested for circulating epithelial cells. Patients with positive tests should be followed-up immediately and aggressively. Patients with negative results may wait the three months for the repeat pap. This would simplify the decision making process for the physician and health professionals and help the patient trust her follow-up procedure. Screening : CellSpotter® image analysis may be used for screening of the general population with the condition that special, tissue specific antibodies would be used on a second test on all abnormal samples.
  • Identification of CTC in a patient may indicate that there is a primary malignancy that has started or is starting the process of metastasis. If these cells are identified as of the tissue of origin with new markers, then organ specific tests, like CT guided fine needle aspirations (FNA) can be used to verify the presence or absence of such malignancies. Patients where a primary cannot be identified may be followed-up with repeat tests after establishing an individual base line.
  • FNA CT guided fine needle aspirations
  • WO 99/41613 describes methods and reagents for detecting, enumerating and characterizing intact rare carcinoma cells in the blood.
  • the methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris- Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system.
  • the Examples show the importance of not only analyzing Obvious or Intact CTC, but Suspect CTC or damaged fragments, clusters of CTC, and debris. It is possible to mimic the damage that forms fragments and debris. It is also possible to inhibit further damage of CTC between the blood draw and sample processing through the use of stabilizing agents.
  • the invention provides a method of testing for the presence of CTCs according to claim 1.
  • Magnetic particles can be classified on the basis of size; large (1.5 to about 50 microns), small (0.7-1.5 microns), or colloidal ( ⁇ 200nm), which are also referred to as nanoparticles.
  • Nanoparticles also known as ferrofluids or ferrofluid-like materials, have many of the properties of classical ferrofluids, and are sometimes referred to herein as colloidal, superparamagnetic particles.
  • Small magnetic particles of the type described above are quite useful in analyses involving bio-specific affinity reactions, as they are conveniently coated with biofunctional polymers (e.g., proteins), provide very high surface areas and give reasonable reaction kinetics.
  • biofunctional polymers e.g., proteins
  • Magnetic particles ranging from 0.7-1.5 microns have been described in the patent literature, including, by way of example, US Patent Nos. 3,970,518 ; 4,018,886 ; 4,230,685 ; 4,267,234 ; 4,452,773 ; 4,554,088 ; and 4,659,678 . Certain of these particles are disclosed to be useful solid supports for immunological reagents.
  • the preferred magnetic particles for use in carrying out this invention are particles that behave as colloids. Such particles are characterized by their sub-micron particle size, which is generally less than about 200nm, and their stability to gravitational separation from solution for extended periods of time. In addition to the many other advantages, this size range makes individual particles essentially invisible to analytical techniques commonly applied to cell analysis. Particles within the range of 90-150nm and having between 70-90% magnetic mass are contemplated for use in the present invention. Suitable magnetic particles are composed of a crystalline core of superparamagnetic material surrounded by molecules which are bonded, e.g., physically absorbed or covalently attached, to the magnetic core and which confer stabilizing colloidal properties.
  • the coating material should preferably be applied in an amount effective to prevent non-specific interactions between biological macromolecules found in the sample and the magnetic cores.
  • biological macromolecules may include carbohydrates such as sialic acid residues on the surface of non-target cells, lectins, glycproteins, and other membrane components.
  • the material should contain as much magnetic mass per nanoparticle as possible.
  • the size of the magnetic crystals comprising the core is sufficiently small that they do not contain a complete magnetic domain.
  • the size of the nanoparticles is sufficiently small such that their Brownian energy exceeds their magnetic moment. As a consequence, North Pole, South Pole alignment and subsequent mutual attraction/repulsion of these colloidal magnetic particles does not appear to occur even in moderately strong magnetic fields, contributing to their solution stability.
  • magnetic particles should be separable in high magnetic gradient external field separators. That characteristic facilitates sample handling and provides economic advantages over the more complicated internal gradient columns loaded with ferromagnetic beads or steel wool.
  • Magnetic particles having the above-described properties can be prepared by modification of base materials described in U.S. Patents #4,795,698 , #5,597,531 , and #5,698,27 .
  • the non-specific binding of cells from whole blood with these particles was 0.3%, which is significantly better than those, produced from '531.
  • the non-specific binding of cells from whole blood with these particles was 0.3%, which is significantly better than those, produced from '531.
  • from 10ml of whole blood there would be about 200,000 non-target cells that would also be isolated with the cells targeted for enrichment.
  • base coated particles of mean diameter 100nm can be produced which contain at best trace amounts of material smaller than 80nm or over 130nm.
  • material of about 120nm can be made with no appreciable material smaller than 90-95nm and over 160nm.
  • Such materials performed optimally with regard to recovery and could be made sub-optimal by the inclusion of 60-70nm nanoparticles.
  • the preferred particle size range for use in practicing this invention is 90-150nm for base coated magnetic particles, e.g., BSA-coated magnetite.
  • high gradient magnetic separation with an external field device employing highly magnetic, low non-specific binding, colloidal magnetic particles is the method of choice for separating a cell subset of interest from a mixed population of eukaryotic cells, particularly if the subset of interest comprises but a small fraction of the entire population.
  • Such materials because of their diffusive properties, readily find and magnetically label rare events, such as tumor cells in blood.
  • the magnetic particles must be specific for epitopes that are not present on hematopoeitic cells.
  • Tumor cells were identified by the expression of the cytoskeletal proteins cytokeratin (CK+), the absence of the common leukocyte antigen CD45 (CD45-) and the presence of nucleic acids (NA+) by multicolor fluorescence analysis. Rare events or rare cells can be immunophenotyped by both flowcytometry and fluorescence microscopy.
  • CK+ cytoskeletal proteins cytokeratin
  • CD45- common leukocyte antigen CD45
  • NA+ nucleic acids
  • Flowcytometric analysis excels in its ability to reproducibly quantify even low levels of fluorescence whereas microscopy has the better specificity as morphological features can aid in the classification of the immunophenotypically identified objects.
  • biological specimen or “biological sample” may be used interchangeably, and refer to a small potion of fluid or tissue taken from a human test subject that is suspected to contain cells of interest, and is to be analyzed.
  • a biological specimen refers to the fluidic portion, the cellular portion, and the portion containing soluble material.
  • Biological specimens or biological samples include, without limit bodily fluids, such as peripheral blood, tissue homogenates, nipple aspirates, colonic lavage, sputum, bronchial (alveolar) lavage, pleural fluids, peritoneal fluids, pericardial fluids, urine, and any other source of cells that is obtainable from a human test subject.
  • An exemplary tissue homogenate may be obtained from the sentinel node in a breast cancer patient.
  • rare cells is defined herein as cells that are not normally present in biological specimens, but may be present as an indicator of an abnormal condition, such as infectious disease, chronic disease, injury, or pregnancy. Rare cells also refer to cells that may be normally present in biological specimens, but are present with a frequency several orders of magnitude less than cells typically present in a normal biological specimen.
  • determinant when used in reference to any of the foregoing target bioentities, refers broadly to chemical mosaics present on macromolecular antigens that often induce an immune response. Determinants may also be used interchangeably with “epitopes”.
  • a determinant refers to that portion of the target bioentity involved in, and responsible for, selective binding to a specific binding substance (such as a ligand or reagent), the presence of which is required for selective binding to occur.
  • determinants are molecular contact regions on target bioentities that are recognized by agents, ligands and/or reagents having binding affinity therefor, in specific binding pair reactions.
  • binding pair includes antigen-antibody, receptor-hormone, receptor-ligand, agonist-antagonist, lectin-carbohydrate, nucleic acid (RNA or DNA) hybridizing sequences, Fc receptor or mouse IgG-protein A, avidin-biotin, streptavidin-biotin and virus-receptor interactions.
  • detectably label is used to herein to refer to any substance whose detection or measurement, either directly or indirectly, by physical or chemical means, is indicative of the presence of the target bioentity in the test sample.
  • useful detectable labels include, but are not limited to the following: molecules or ions directly or indirectly detectable based on light absorbance, fluorescence, reflectance, light scatter, phosphorescence, or luminescence properties; molecules or ions detectable by their radioactive properties; molecules or ions detectable by their nuclear magnetic resonance or paramagnetic properties.
  • Biospecific ligands and reagents have specific binding activity for their target determinant yet may also exhibit a low level of non-specific binding to other sample components.
  • stage cancer is used interchangeably herein with “Stage I” or “Stage II” cancer and refers to those cancers that have been clinically determined to be organ-confined. Also included are tumors too small to be detected by conventional methods such as mammography for breast cancer patients, or X-rays for lung cancer patients. While mammography can detect tumors having approximately 2 x 10 8 cells, the methods of the present invention should enable detection of circulating cancer cells from tumors approximating this size or smaller.
  • enrichment refers to the process of substantially increasing the ratio of target bioentities (e.g., tumor cells) to non-target materials in the processed analytical sample compared to the ratio in the original biological sample.
  • target bioentities e.g., tumor cells
  • red cells are not counted when assessing the extent of enrichment.
  • circulating epithelial cells may be enriched relative to leucocytes to the extent of at least 2,500 fold, more preferably 5,000 fold and most preferably 10,000 fold.
  • anti-coagulant or "anti-coagulating agent” may be used interchangeably, and refer to compositions that are added to biological specimens for the purpose of inhibiting any undesired natural or artificial coagulation.
  • An example of coagulation is blood clotting and common anti-coagulants are chelating agents, exemplified by ethylenediamine tetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA), 1,2-diaminocyclohexane tetraacetic acid (DCTA), ethylenebis(oxyethylenenitrilo) tetraacetic acid (EGTA), or by complexing agents, such as heparin, and heparin species, such as heparin sulfate and low-molecular weight heparins.
  • EDTA ethylenediamine tetraacetic acid
  • DTPA diethylenetriamine pentaacetic acid
  • DCTA 1,2-diaminocyclohexane tetraace
  • clumping' This may be further collectively defined as “clumping' or “clump formation”.
  • clumps must be differentiated from “clusters” or aggregates of CTC that are counted as a single Intact CTC if they meet the classification criteria for Intact CTC.
  • Clusters of CTC are believed to have greater proliferative potential than single CTC and their presence is thus diagnostically highly significant.
  • One possible cause for an increased propensity to establish secondary metastatic tumor sites may be the virtue of their adhesiveness.
  • An even more likely cause is the actual size of a CTC cluster; larger clusters will become lodged in small diameter capillaries or pores in bone. Once there, the viability of the cells in the cluster would determine the chance of survivability at the new metastatic site.
  • the ideal "stabilizer” or “preservative” is defined as a composition capable of preserving target cells of interest present in a biological specimen, while minimizing the formation of interfering aggregates and cellular debris in the biological specimen, which in any way can impede the isolation, detection, and enumeration of targets cells, and their differentiation from non-target cells.
  • a stabilizing agent when combined with an anti-coagulating agent, a stabilizing agent should not counteract the anti-coagulating agent's performance. Conversely, the anti-coagulating agent should not interfere with the performance of the stabilizing agent.
  • the disclosed stabilizers also serve a third function of fixing, and thereby stabilizing, permeabilized cells, wherein the expressions "permeabilized” or “permeabilization” and “fixing”, “fixed” or “fixation” are used as conventionally defined in cell biology.
  • stabilizing agents herein implies using these agents at appropriate concentrations or amounts, which would be readily apparent to one skilled in cell biology, where the concentration or amount is effective to stabilize the target cells without causing damage.
  • concentration or amount is effective to stabilize the target cells without causing damage.
  • One using the compositions, methods, and apparatus of this invention for the purpose of preserving rare cells would obviously not use them in ways to damage or destroy these same rare cells, and would therefore inherently select appropriate concentrations or amounts.
  • the formaldehyde donor imidazolidinyl urea has been found to be effective at a preferred concentration of 0.1-10%, more preferably at 0.5-5% and most preferably at about 1-3% of the volume of said specimen.
  • An additional agent, such as polyethylene glycol has also been found to be effective, when added at a preferred concentration of about 0.1 % to about 5%, more preferably about 0.1 % to about 1%, and most preferably about 0.1% to about 0.5% of the specimen volume.
  • a stabilizing agent must be capable of preserving a sample for at least a few hours. However, it has been shown that samples can be stabilized for at least up to 72 hours. Such long-term stability is important in cases where the sample is obtained in a location that is distant to the location where processing and analysis will occur. Furthermore, the sample must be stabilized against mechanical damage during transport.
  • Stabilizing agents are necessary to discriminate between in vivo tumor cell disintegration and disintegration due to in vitro sample degradation. Therefore, stabilizing agent compositions, as well as methods and apparatus for their use, are described in WO 03/018757, published on 6th March 2003 .
  • Optunous cells or “intact cells” may be used interchangeably, and refer to cells found during imaging analysis that contain nucleic acid and cytokeratin. These cells are usually visually round or oval, but may sometimes be polygonal or elongated, and appear as individual cells or clusters of cells.
  • the nucleic acid area i.e. labeled by nucleic acid dye
  • the cytoplasmic area i.e. labeled by anti-cytokeratin
  • Suspect cells may be used interchangeably, and refer to cells found during imaging analysis that resemble intact cells, but are not as visually distinct as intact cells. Based on imaging analysis, there are a number of possible types of Suspect cells, including:
  • debris refers to unclassified objects that are specifically or non-specifically labeled during processing, and are visible as images during analysis, but are distinct from intact and/or Suspect cells. For example, it has been observed that damaged cells will release nuclear material. During processing, this nuclear material may be non-specifically magnetically labeled, and subsequently labeled with the nucleic acid stain. During analysis, the magnetically labeled and stained nuclear material can be observed when it has cytokeratin still attached. There are other objects that are similarly magnetically selected and stained which appear during analysis that are classified as debris.
  • morphological analysis refers to visually observable characteristics for an object, such as size, shape, or the presence/absence of certain features. In order to visualize morphological features, an object is typically non-specifically stained.
  • epitopical analysis refers to observations made on objects that have been labeled for certain epitopes. In order to visualize epitopic features, an object is typically specifically stained or labeled. Morphological analysis may be combined with epitopical analysis to provide a more complete analysis of an object.
  • Figure 1 is a model of various CTC stages, including shedding and metastasis.
  • Figure 1a shows these stages for cells, clusters, fragments, and debris.
  • Figure 1b shows actual images from samples at these same stages.
  • the images of cells clusters, fragments, and debris were taken from CellSpotter® analyses of patient samples.
  • the images of tissue samples (Origin and Metastatic sites) were taken from elsewhere ( Manual of Cytology, American Society of Clinical Pathologists Press. 1983 ).
  • a single cell shed from a primary tumor into the blood either survives or dies in blood. If it survives, it may possibly divide in blood, or colonize at a secondary site. If the cell dies, depending on the method, the cell degrades into various types of fragments or debris.
  • Another possibility is a cluster of cells is shed from a primary tumor into the blood, where it may dissociate into single cells, or remain intact, and colonize at a secondary site. If the cluster dissociates, it can behave similar to the single cell described above. If the cluster remains intact, it is more likely to for a secondary colony for the reasons described above, which includes the large diameter cluster becoming lodged in a small diameter capillary. Once lodged, if the cells are viable, the cluster would form a new tumor.
  • Nuclear morphology is used to determine the activity status and abnormality of a cell. Chromatin clumping, the presence or absence of nucleoli, and hyperchromasia, are criteria used to determine whether a cell is benign or malignant, reacting to a immune response, or reacting to treatment. The cytoplasmic morphology is used to determine the level of differentiation (i.e. tissue of origin). For example, cytomplasmic morphology can classify cells as squamous versus glandular.
  • the surviving battered tumor cells present in the peripheral circulation may be further stressed and damaged by turbulence during blood draw into an evacuated tube and by specimen processing, e.g. transport of the blood tube and mixing prior to analysis.
  • specimen processing e.g. transport of the blood tube and mixing prior to analysis.
  • Such mechanical damage is additional to on-going immunological, apoptotic, and necrotic processes leading to destruction of CTC that occur in vitro in a time dependent manner.
  • the longer the specimen is stored the greater the loss of CTC, and the larger the amounts of interfering debris and/or aggregates. Indeed, data presented in this specification ( Figures 2 and 3 ) show dramatic declines in CTC counts in several blood specimens stored at room temperature for 24hrs or longer, indicating substantial in vitro destruction of CTC after blood draw.
  • the initiating event in the sequence resulting from the microtubule stabilizing effects of paclitaxel which in turn may activate the pro-apoptotic gene Bim that senses cytoskeletal distress.
  • Further evidence of caspase-cleaved cytokeratin resulting from apoptosis was obtained with the M30 Cytodeath antibody (Roche Applied Science, Mannheim, Germany) that recognizes an epitope of cytokeratin 18 that is only exposed following caspase cleavage in early apoptosis. Only the paclitaxel treated LnCaP cells stained with M30 and most of the dimmer cytokeratin cells stained with M30, which is consistent with cells undergoing apoptosis.
  • the enumeration of circulating epithelial cells in blood using the methods and compositions of a preferred embodiment of the present invention is achieved by immunomagnetic selection (enrichment) of epithelial cells from blood followed by the analysis of the samples.
  • the immunomagnetic sample preparation is important for reducing sample volume and obtaining as much as a 10 4 fold enrichment of the target (epithelial) cells.
  • the reagents used for the multi-parameter flow cytometric analysis are optimized such that epithelial cells are located in a unique position in the multidimensional space created by the listmode acquisition of two light scatter and three fluorescence parameters. These include
  • the method of analysis of the enriched tumor cell population will depend on the intended use of the invention. For example, in screening for cancers or monitoring for recurrence of disease, as described hereinbelow, the numbers of circulating epithelial cells can be very low. Since there is some "normal" level of epithelial cells, (very likely introduced during venipuncture), a method of analysis that identifies epithelial cells as normal or tumor cells is desirable. In that case, microscopy based analyses may prove to be the most accurate. Such examination might also include examination of morphology, identification of known tumor diathesis associated molecules (e.g., oncogenes).
  • Magnetic nanoparticles labeled with monoclonal antibodies identifying epithelial cell adhesion molecule were used to label and separate by magnetic means epithelial cells from hematopoietic cells as taught in commonly-owned US Patent #6,365,362 , and US 2002/0172987 A1, published on 21st November 2002 .
  • EpCAM epithelial cell adhesion molecule
  • a monoclonal antibody that recognizes keratins 4, 5, 6, 8, 10, 13, and 18, conjugated to Phycoerythrin (CK-PE) was used to identify epithelial cells and a monoclonal antibody that recognizes CD45 was used to identify leukocytes and identify hematopoietic cells that non-specifically bind to cytokeratin.
  • CD45 For multicolor fluorescent microscopy (CellSpotter ® ) analysis CD45 was conjugated to Allophycocyanin (CD45-APC, Caltag, CA) whereas for flow cytometric analysis peridinin chlorophyll protein conjugated CD45 (CD45-PerCP, BDIS San Jose, CA) was used.
  • the nucleic acid specific dye DAPI (4,6-diamidino-2-phenylindole) was used to identify and visualize the nucleus in the CellSpotter ® system and the nucleic acid dye in the Procount system (BDIS, San Jose,CA) was used to identify cells by flow cytometry.
  • Samples were analyzed on a FACSCalibur flow cytometer equipped with a 488nm Argon ion laser (BDIS, San Jose, CA). Data acquisition was performed with CellQuest (BDIS, San Jose, CA) using a threshold on the fluorescence of the nucleic acid dye. The acquisition was halted after 8000 beads or 80% of the sample was analyzed. Multiparameter data analysis was performed on the listmode data (Paint-A-Gate Pro , BDIS, San Jose, CA). Analysis criteria for CTC events included size defined by forward light scatter, granularity defined by orthogonal light scatter, positive staining with the PE-labeled anti-cytokeratin MAb and no staining with the PerCP-labeled anti-CD45 Mab. For each sample, the number of events present in the region typical for epithelial cells was multiplied by 1.25 to account for the sample volume not analyzed by flow cytometry.
  • FIG. 2 Panels A, B and C shows the flow cytometric analysis of a blood sample of a patient with metastatic prostate cancer.
  • Two vertical lines in Panel B illustrate the low and high boundary of nucleic acid (NAD) content of leukocytes (red dots).
  • CTC candidates express Cytokeratin (CK+), lack CD45 (CD45-) and contain nucleic acids (NAD+).
  • CTC candidates having NAD equal or higher than leukocytes are considered cells and are depicted black.
  • CK+, CD45- events with NAD content less than leukocytes were not considered target cells and depicted blue. The blue events were clearly smaller as compared with the black colored CTC as evident by the smaller forward light scatter signals.
  • the CellSpotter ® system consists of a microscope with a Mercury Arc Lamp, a 10X objective, a high resolution X, Y, Z stage and a four-filter cube changer. Excitation, dichroic and emission filters in each of four cubes were for DAPI 365nm/400nm/400nm, for DiOC16 480nm/ 495nm/ 510nm, for PE 546nm/ 560nm/ 580nm and for APC 620nm/ 660nm/ 700nm. Images were acquired with a digital camera connected to a digital frame grabber.
  • the surface of the chamber is 80.2 mm 2 and 4 rows of 35 images for each of the 4 filters resulting in 560 images have to be acquired to cover the complete surface.
  • the CellSpotter ® acquisition program automatically determines the region over which the images are to be acquired, the number of images to acquire, the position of each image and the microscope focus to use at each position. All the images from a sample are logged into a directory that is unique to the specific sample identification. An algorithm is applied on all of the images acquired from a sample to search for locations that stain for DAPI and CK-PE. If the staining area is consistent with that of a potential tumor cell (DAPI+, CK-PE+) the software stores the location of these areas in a database. The software displays thumbnails of each of the boxes and the user can confirm that the images represented in the row are consistent with tumor cells, or stain with the leukocyte marker CD45. The software tabulates the checked boxes for each sample and the information is stored in the database.
  • Figure 3 shows examples of CellSpotter ® analysis of a blood sample from a patient with metastatic prostate cancer. Regions that potentially contain tumor cells are displayed in rows of thumbnails. The ruler in the left lower corner of the figure indicates the sizes of the thumbnails. From right to left these thumbnails represent nuclear (DAPI), cytoplasmic cytokeratin (CK-PE), control cells stained with a membrane dye (DiOC 16 (3)) and surface CD45 (CD45-APC) staining. The composite images shown at the left show a false color overlay of the purple nuclear (DAPI) and green cytoplasmic (CK-PE) staining.
  • DAPI nuclear
  • CK-PE cytoplasmic cytokeratin
  • CD45-APC surface CD45
  • the check box beside the composite image allow the user to confirm that the images represented in the row are consistent with tumor cells and the check box beside the CD45-APC image is to confirm that a leukocyte or tumor cell stain non-specifically.
  • the software detected 2761 rows of thumbnails that demonstrated staining consistent with tumor cells. Eighteen of the 2761 rows are shown in the figure labeled 1631-1640 and 1869-1876. Rows numbered 1631, 1636, 1638, 1640, and 1873-1876 are checked off and display features of CTC defined as a size greater than 4 ⁇ m, the presence of a nucleus surrounded by cytoplasmic cytokeratin staining and absence of DiOC 16 (3) and CD45 staining.
  • the cell in row 1638 is large and the one in row 1640 is significantly smaller.
  • the immunophenotype of the events in rows 1634 and 1869 are consistent with tumor cells but their morphology is not consistent with intact cells.
  • the thumbnails in row 1869 shows a large nucleus and speckled cytoplasmic due to retraction of cytoskeletal proteins consistent with apoptosis of the cell.
  • the thumbnail in row 1634 shows a damaged cell that appears to extrude its nucleus.
  • the thumbnail shown in row 1632 shows a cell that stains both with cytokeratin as well as CD45 and is either a tumor cell non-specifically binding to CD45 or a leukocyte non specifically staining with cytokeratin.
  • thumbnails 1633, 1635, 1637, 1639, 1870 and 1872 shows cytokeratin staining objects that are larger that 4 ⁇ m but have no resemblance to cells.
  • the cytokeratin staining objects in thumbnails 1637, 1639 and 1872 are in close proximity of a leukocyte.
  • FIG. 4 displays examples of the three categories of CTC isolated from a single tube of blood of a patient with metastatic prostate cancer undergoing therapy.
  • Intact tumor cells shown in Figure 3A were defined as objects larger than 4 ⁇ m with a relatively smooth cytoplasmic membrane, cytoskeletal proteins throughout the cytoplasm, and an intact nucleus encompassed within the nucleus.
  • Damaged CTC shown in Figure 4B were defined as objects larger than 4 ⁇ m with speckled cytokeratin staining or ragged cytoplasmic membrane, and a nucleus associated with the cytokeratin staining.
  • Tumor cell fragments shown in Figure 4C were defined as round cytokeratin staining objects larger than 4 ⁇ m with or without association of nuclear material that had no morphological resemblance to a cell.
  • CTC were enumerated in 18 blood samples of prostate cancer patients and 27 samples from healthy individuals by both flow cytometry and CellSpotter ® .
  • the results shown in Table 1 were sorted by increasing number of intact CTC detected by CellSpotter ® .
  • Table 1- Enumeration of CTC by CellSpotter ® and flow cytometry in 18 blood samples of prostate cancer patients and 27 samples from healthy individuals.
  • the proportion of intact CTC clearly constituted the smallest fraction of CTC and ranged from 0% to 22% of all CTC (mean 4%).
  • the proportion of damaged CTC ranged from 1 % to 100% (mean 34%) and the CTC fragments constituted the largest portion of CTC ranging from 0% to 93% (mean 62%).
  • CTC detected by both flow cytometry and CellSpotter ® are comprised of intact cells and cells of cells at various stages of disintegration.
  • the apoptosis induced in vitro by paclitaxel suggests that the detected CTC in patient blood samples are undergoing apoptosis, necrosis, or in vivo damage to a varying degree caused by the treatment or therapy, mechanical damage by passage through the vascular system, or by the immune system.
  • the 100 ⁇ l assay categorizes cells based on properties such as size and staining intensity.
  • Obvious CTC have bright nucleic acid staining (similar to leukocytes), positive EpCAM antigen staining and size similar to leukocytes or larger.
  • Suspect CTC are any objects positive for EpCAM antibody but not characterized as Obvious CTC (i.e. dim nucleic acid, size smaller than leukocytes).
  • the assay identifies objects from both categories.
  • Figure 5 shows the presence of Obvious and Suspect CTC in blood as determined by the 100 ⁇ l assay.
  • the Suspect CTC are not created during sample processing ( in vitro damage) as the 100 ⁇ l assay is a direct assay and does not involve any separation or wash steps.
  • the data above also show there is a relationship between the number of Obvious and Suspect CTC.
  • the number of Suspect CTC seems to increase as the number of Obvious CTC increases.
  • the slope of 2.92 indicates the proportion of Suspect CTC present in sample when compared to Obvious CTC.
  • Suspect CTC are also seen in the ferrofluid-selection assay, and have properties similar to Suspect CTC detected in the blood by the direct assay. It is important to include Suspect CTC in addition to Obvious CTC in total tumor cell count.
  • CTC recoveries of CTC from some other clinical samples have been as low as 20%. There may be several factors that contribute for a lower recovery, such as EpCAM positive/cytokeratin negative cells, cytokeratin dim cells, and mucin on the cell surface inhibiting the ability of ferrofluid to bind cells.
  • Ratio Obvious CTC / Total CTC
  • Ratios near 1.0 indicate the Total CTC are Obvious CTC
  • ratios near 0.0 indicate more Suspect CTC or debris.
  • Progressive indicates the lesion increasing in size
  • Partial Response indicates a response to treatment where the Ratio is relatively low
  • Stabilized indicates no change, or reduction in lesion size.
  • a positive Change indicates an increase in the number of Intact CTC, corresponding to the progression of the disease.
  • a negative Change indicates a decrease in the number of Intact CTC, or a possible increase in the number of Suspect CTC and/or debris, corresponding to a response to treatment.
  • Enumeration of tumor cell debris may prove more significant in cancer diagnostics and therapeutics than detection of large proliferative cell clusters. Since debris particles in the size range, probably about 1-3 ⁇ m (the size of platelets), have been observed to be present in much larger amounts than intact cells, they may constitute a separate, independent, and possibly more sensitive marker than intact tumor cells. The presence of damaged CTC may be particularly relevant in detecting early-stage cancer, when the immune system is intact and most active. Similarly, dramatic increases in debris during therapy may suggest breakdown of both circulating and tissue tumor cells (i.e. therapeutic effectiveness), paralleling the massive release of cellular components like calcium observed during tumor disintegration.
  • Such debris may be detectable in blood without enrichment, or with minimal enrichment in the buffy coat layer and constitute an alternative, and potentially simpler diagnostic tool than intact cell enrichment/analysis. Since morphology is lost in CTC debris, detection could be done by flow cytometry as long as the debris is stained for the appropriate determinants, such as cytokeratin.
  • damaged or fragmented CTC with or without DNA are theoretically to be expected, and therefore are not undesirable events in specimens from patients undergoing effective therapy and in untreated patients with strong immune systems.
  • the ratio or % of intact CTC to total detectable events may prove to be a more useful parameter to the clinician in assessing a patient's immune system or response to therapy.
  • the normal immune defenses, especially activated neutrophils also can damage or destroy CTC as foreign species by a process called "extracellular killing" even if the CTC are larger than the neutrophils. It does not seem surprising to find only a small percentage of the shed CTC as intact cells, unless the immune system is overwhelmed in the late stages of disease or therapy is ineffective.
  • Examples of different types of cancer that may be detected using the compositions, methods and kits of the present invention include apudoma, choristoma, branchioma, malignant carcinoid syndrome, carcinoid heart disease, carcinoma e.g., Walker, basal cell, basosquamous, Brown-Pearce, ductal, Ehrlich tumor, in situ, Krebs 2, merkel cell, mucinous, non-small cell lung, oat cell, papillary, scirrhous, bronchiolar, bronchogenic, squamous cell and transitional cell reticuloendotheliosis, melanoma, chondroblastoma, chondroma, chondrosarcoma, fibroma, fibrosarcoma, giant cell tumors, histiocytoma, lipoma, liposarcoma, mesothelioma, myxoma, myxosarcoma, osteoma, osteosarcom
  • the present invention is not limited to the detection of circulating epithelial cells and/or clusters, fragments, or debris.
  • endothelial cells have been observed in the blood of patients having a myocardial infarction.
  • Endothelial cells, myocardial cells, and virally infected cells, like epithelial cells, have cell type specific determinants that are recognized by available monoclonal antibodies.
  • the methods and the kits of the invention may be adapted to detect such circulating endothelial cells.
  • the invention allows for the detection of bacterial cell load in the peripheral blood of patients with infectious disease, who may also be assessed using the compositions, methods and kits of the invention. It would be reasonable to expect that these rare cells will behave similarly in circulation, and that fragments and/or debris will be present in similar conditions as those described hereinabove.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Claims (7)

  1. Testverfahren bezüglich des Vorliegens von zirkulierenden Tumorzellen (CTC-Zellen) in einer Blutprobe, das Folgendes aufweist:
    a. Kontaktieren der Blutprobe mit Imidazolidinylharnstoff und gegebenenfalls Polyethylenglykol zum Zeitpunkt der Blutabnahme;
    b. Vorbereiten einer magnetisch markierten Probe durch Vermischen der Blutprobe mit kolloidalen magnetischen Partikeln, die mit einem ersten biospezifischen Liganden verbunden sind, wobei die kolloidalen magnetischen Partikel im Bereich von 90 nm bis 150 nm liegen und zwischen 70 und 90% magnetische Masse aufweisen, wobei die Blutprobe eine gemischte Zellpopulation mit dem Verdacht auf intakte CTC-Zellen und weiter Folgendes aufweist:
    i. von CTC-Zellen abgeleitete Zellfragmente; oder
    ii. von CTC-Zellen abgeleitete Zelltrümmer;
    wobei der erste biospezifische Ligand spezifisch mit den intakten CTC-Zellen und den Zellfragmenten oder den Zelltrümmern reagiert, wobei andere Komponenten der Probe im Wesentlichen ausgeschlossen sind;
    c. Kontaktieren von Material aus der magnetisch markierten Probe mit mindestens einem zusätzlichen biospezifischen Liganden, der die intakten CTC-Zellen und die Zellfragmente oder die Zelltrümmer spezifisch markiert, wobei andere Komponenten der Probe im Wesentlichen ausgeschlossen sind;
    d. Analyse des sich ergebenden Materials auf das Vorliegen der markierten CTC-Zellen und der markierten Zellfragmente oder der markierten Zelltrümmer.
  2. Verfahren nach Anspruch 1, wobei nach dem Schritt der Vorbereitung der magnetisch markierten Probe die Probe einem hochgradienten Magnetfeld ausgesetzt wird, um einen separaten magnetisch markierten Bruchteil zu erzeugen, der mit den intakten CTC-Zellen und den Zellfragmenten oder den Zelltrümmern angereichert ist.
  3. Verfahren nach einem der vorstehenden Ansprüche, wobei die Analyse aus der Gruppe ausgewählt wird, die Folgendes aufweist: Multiparameter-Flusszytometrie, Immunofluoreszenz-Mikroskopie, Laserscanning-Zytometrie, Hellfeldbasis-Bildanalyse, Kapillarvolumetrie, Spektralbildanalyse, manuelle Zellanalyse und automatisierte Zellanalyse.
  4. Verfahren nach einem der vorstehenden Ansprüche, wobei die Analyse weiter die Klassifizierung der Zellfragmente oder der Zelltrümmer auf der Grundlage ihres Ursprungs hinsichtlich der Entstehung durch Apoptose oder Nekrose aufweist.
  5. Verfahren nach Anspruch 4, wobei die Analyse weiter die Klassifizierung der Zellfragmente oder der Zelltrümmer auf der Grundlage ihres Ursprungs hinsichtlich der Entstehung durch mechanische Beschädigung, arzneimittelinduzierte Schäden oder immunologische Schäden aufweist.
  6. Verfahren nach Anspruch 4, wobei die Klassifizierung auf mindestens einem Element der Gruppe basiert, die Folgendes aufweist: morphologische Analyse und epitopische Analyse.
  7. Verfahren nach einem der vorstehenden Ansprüche, wobei die Probe zusätzlich zu intakten CTC-Zellen CTC-Cluster enthält.
EP02761478A 2001-08-23 2002-08-23 Analyse zirkulierender tumorzellen, fragmente und trümmer Expired - Lifetime EP1425294B2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31415101P 2001-08-23 2001-08-23
US314151P 2001-08-23
US36962802P 2002-04-03 2002-04-03
US369628P 2002-04-03
PCT/US2002/026861 WO2003019141A2 (en) 2001-08-23 2002-08-23 Analysis of circulating tumor cells, fragments, and debris

Publications (4)

Publication Number Publication Date
EP1425294A2 EP1425294A2 (de) 2004-06-09
EP1425294A4 EP1425294A4 (de) 2005-11-16
EP1425294B1 EP1425294B1 (de) 2008-07-16
EP1425294B2 true EP1425294B2 (de) 2012-12-12

Family

ID=26979228

Family Applications (2)

Application Number Title Priority Date Filing Date
EP02768676A Withdrawn EP1425383A4 (de) 2001-08-23 2002-08-23 Stabilisierung von zellen und biologischen präparaten zur analyse
EP02761478A Expired - Lifetime EP1425294B2 (de) 2001-08-23 2002-08-23 Analyse zirkulierender tumorzellen, fragmente und trümmer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP02768676A Withdrawn EP1425383A4 (de) 2001-08-23 2002-08-23 Stabilisierung von zellen und biologischen präparaten zur analyse

Country Status (11)

Country Link
EP (2) EP1425383A4 (de)
JP (3) JP2005501236A (de)
KR (2) KR20040030984A (de)
CN (2) CN1596265A (de)
AT (1) ATE401574T1 (de)
AU (2) AU2008288601B2 (de)
BR (2) BR0212125A (de)
CA (2) CA2457891C (de)
DE (1) DE60227678D1 (de)
IL (2) IL160209A0 (de)
WO (2) WO2003018757A2 (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863012B2 (en) 2004-02-17 2011-01-04 Veridex, Llc Analysis of circulating tumor cells, fragments, and debris
CA2457891C (en) * 2001-08-23 2019-10-01 Immunivest Corporation Method of preservation of circulating tumor cells
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
MXPA04011129A (es) 2002-05-13 2005-02-17 Becton Dickinson Co Sistema de recoleccion de muestra de inhibidor de proteasa.
ES2375724T3 (es) 2002-09-27 2012-03-05 The General Hospital Corporation Dispositivo microflu�?dico para seperación de células y sus usos.
EP1413874A1 (de) 2002-10-16 2004-04-28 Streck Laboratories, Inc. Verfahren und Vorrichtung zum Sammeln und Konservieren von Zellen für die Analyse
EP1597353B1 (de) 2003-02-27 2010-11-24 Veridex, LLC ZIRKULIERENDE TUMORZELLEN (CTC's): FRÜHE BEURTEILUNG VON TIME-TO-PROGRESSION, ÜBERLEBEN UND ANSPRECHEN AUF THERAPIE BEI PATIENTEN MIT METASTASIERTEM KREBS
WO2005028663A2 (en) * 2003-09-18 2005-03-31 Immunivest Corporation Operator independent programmable sample preparation and analysis system
JP2008533487A (ja) * 2005-03-14 2008-08-21 イムニベスト・コーポレイション 循環腫瘍細胞を用いる転移性乳癌患者の療法中の各追跡期間ポイントでの無増悪および全生存を予測する方法
US20070196820A1 (en) 2005-04-05 2007-08-23 Ravi Kapur Devices and methods for enrichment and alteration of cells and other particles
US20080038725A1 (en) 2005-06-20 2008-02-14 Yuling Luo Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US8337755B2 (en) 2006-03-13 2012-12-25 Veridex, Llc Operator independent programmable sample preparation and analysis system
CA2653745C (en) 2006-06-02 2013-11-19 Pfizer Products Inc. Circulating tumor cell assay
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
EP2029779A4 (de) 2006-06-14 2010-01-20 Living Microsystems Inc Verwendung hoch paralleler snp-genotypisierung zur fötalen diagnose
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
CN101583722A (zh) 2006-07-14 2009-11-18 阿维瓦生物科学股份有限公司 从生物学样品检测稀有细胞的方法和组合物
HUE028487T2 (en) * 2007-02-27 2016-12-28 Sentoclone Int Ab Multiplex detection of tumour cells using a panel of agents binding to extracellular markers
US8003314B2 (en) 2007-04-16 2011-08-23 Diagnostic Hybrids, Inc. Methods for direct fluorescent antibody virus detection in liquids
US20120202189A1 (en) * 2007-04-16 2012-08-09 Diagnostic Hybrids, Inc. Rapid, semi-automated method to detect respiratory virus infected cells in direct specimens
US7828968B2 (en) 2007-08-30 2010-11-09 Veridex, Llc Method and apparatus for imaging target components in a biological sample using permanent magnets
US8110101B2 (en) 2007-08-30 2012-02-07 Veridex, Llc Method and apparatus for imaging target components in a biological sample using permanent magnets
US8071395B2 (en) 2007-12-12 2011-12-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and apparatus for magnetic separation of cells
SMT201700149T1 (it) 2008-09-20 2017-05-08 Univ Leland Stanford Junior Diagnosi non invasiva di aneuploidia fetale mediante sequenziamento
US11634747B2 (en) 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
ES2649572T3 (es) 2009-02-18 2018-01-12 Streck Inc. Conservación de ácidos nucleicos fuera de las células
WO2011038403A1 (en) 2009-09-28 2011-03-31 Yuling Luo Methods of detecting nucleic acid sequences with high specificity
CN107422127A (zh) * 2009-10-21 2017-12-01 斯克里普斯研究所 用非稀有细胞检测稀有细胞的方法
EP2529030B1 (de) 2010-01-29 2019-03-13 Advanced Cell Diagnostics, Inc. Verfahren zum in situ nachweis von nukleinsäuren
WO2011099565A1 (ja) * 2010-02-10 2011-08-18 シスメックス株式会社 血液中癌細胞の検出方法及びそれに用いるプログラム
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
AU2011255641A1 (en) 2010-05-18 2012-12-06 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10179937B2 (en) 2014-04-21 2019-01-15 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US12545960B2 (en) 2010-05-18 2026-02-10 Natera, Inc. Methods for simultaneous amplification of target loci
DE102010020785A1 (de) * 2010-05-18 2011-11-24 Siemens Aktiengesellschaft Vorrichtung und Verfahren zum Erkennen von magnetisch markierten Mikroobjekten
CA2821906C (en) 2010-12-22 2020-08-25 Natera, Inc. Methods for non-invasive prenatal paternity testing
CA2824387C (en) 2011-02-09 2019-09-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20120252038A1 (en) * 2011-04-01 2012-10-04 Chianese David A Steroid receptor assays
EP2704740B1 (de) 2011-05-04 2016-10-05 Streck, Inc. Inaktiviertes schweinegrippe-virus und verfahren zu seiner herstellung
US20140295426A1 (en) * 2011-07-28 2014-10-02 Veridex Llc Methods for Diagnosing Cancer by Characterization of Tumor Cells Associated with Pleural or Serous Fluids
EP4397770A1 (de) 2011-09-26 2024-07-10 PreAnalytiX GmbH Stabilisierung und isolierung extrazellulärer nukleinsäuren
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
US10676780B2 (en) 2011-09-26 2020-06-09 Qiagen Gmbh Stabilisation and isolation of extracellular nucleic acids
KR102037891B1 (ko) * 2012-03-09 2019-10-30 한국전자통신연구원 다중 분리 장치 및 혈중 암세포 분리 방법
US20150148212A1 (en) 2012-05-10 2015-05-28 Konica Minolta, Inc. Process for removing red blood cells and centrifugal tube for blood collection
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
CA2884915C (en) 2012-09-25 2022-05-17 Qiagen Gmbh Stabilisation of biological samples
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
CN110186835B (zh) 2013-03-15 2022-05-31 Gpb科学有限公司 颗粒的片上微流体处理
CN105247042B (zh) 2013-03-15 2021-06-11 普林斯顿大学理事会 用于高通量纯化的方法和设备
CN105283550A (zh) 2013-03-18 2016-01-27 凯杰有限公司 生物样品的稳定化
CN105121643A (zh) * 2013-03-18 2015-12-02 凯杰有限公司 细胞外核酸的稳定化和分离
CA2917912C (en) 2013-07-24 2019-09-17 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
CA2928779A1 (en) * 2013-10-21 2015-04-30 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
WO2015112955A1 (en) 2014-01-27 2015-07-30 Epic Sciences, Inc. Circulating tumor cell diagnostics for prostate cancer biomarkers
WO2015127008A1 (en) 2014-02-21 2015-08-27 Epic Sciences, Inc. Methods for analyzing rare circulating cells
JP6664332B2 (ja) * 2014-03-18 2020-03-13 キアゲン ゲーエムベーハー 細胞外核酸の安定化および単離
CN103940997B (zh) * 2014-03-21 2017-01-04 上海柏慧康生物科技有限公司 一种乳腺癌循环肿瘤细胞检测系统及试剂盒
US12492429B2 (en) 2014-04-21 2025-12-09 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
CN103980365A (zh) * 2014-06-03 2014-08-13 国家纳米科学中心 一种表面固载炭疽致死因子的磁性纳米粒子、其制备方法及用途
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
WO2016004308A1 (en) * 2014-07-02 2016-01-07 Siemens Healthcare Diagnostics Inc. Selective nucleic acid separation
WO2016137915A1 (en) * 2015-02-24 2016-09-01 Siemens Healthcare Diagnostics Inc. Prefixation for increased rare cell recovery
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
DK3294906T3 (en) 2015-05-11 2024-08-05 Natera Inc Methods for determining ploidy
CA2936167A1 (en) * 2015-07-15 2017-01-15 Streck, Inc. Method and device for stabilizing of proteins
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
JP6617495B2 (ja) * 2015-09-18 2019-12-11 東ソー株式会社 腫瘍細胞の検出方法
WO2017079212A1 (en) * 2015-11-04 2017-05-11 Axon Dx, Llc Cell detection, capture, analysis, aggregation, and output methods and apparatus
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
CA3005694A1 (en) 2015-11-20 2017-05-26 Qiagen Gmbh Method of preparing sterilized compositions for stabilization of extracellular nucleic acids
CN105372109A (zh) * 2015-12-15 2016-03-02 苏州药明康德新药开发股份有限公司 添加稳定剂的生物基质的制备方法
PL3422848T3 (pl) * 2016-03-04 2025-05-26 Menarini Silicon Biosystems S.P.A. Konserwowanie składników komórkowych z komórek za pomocą środka konserwującego
CA3014773C (en) 2016-03-07 2025-11-18 Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital NON-INVASIVE MOLECULAR WITRS
WO2017181202A2 (en) 2016-04-15 2017-10-19 Natera, Inc. Methods for lung cancer detection
JP2017219479A (ja) 2016-06-09 2017-12-14 住友電気工業株式会社 微小粒子計測装置及び分析方法
EP3491381B1 (de) 2016-07-29 2025-09-24 Streck LLC Suspensionszusammensetzung zur kontrolle einer hämatologischen analyse
WO2018067517A1 (en) 2016-10-04 2018-04-12 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
KR102476709B1 (ko) 2016-11-21 2022-12-09 나노스트링 테크놀로지스, 인크. 화학적 조성물 및 이것을 사용하는 방법
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
ES2909392T3 (es) 2017-08-02 2022-05-06 Sarstedt Ag & Co Kg Procedimiento y composición para la estabilización de ácidos nucleicos libres de células y células
JP7393328B2 (ja) 2017-09-01 2023-12-06 ジーピービー・サイエンティフィック・インコーポレイテッド マイクロ流体を使用した治療的に活性な細胞を調製する方法
HUE068517T2 (hu) * 2017-10-19 2024-12-28 Streck Llc A hemolízis és a véralvadás szabályozására, valamint az extracelluláris vezikulák stabilizálására szolgáló készítmények
CA3085933A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
EP3781714B1 (de) 2018-04-14 2026-01-07 Natera, Inc. Verfahren zur krebserkennung und -überwachung durch personalisierte detektion zirkulierender tumor-dna
EP3794146B1 (de) 2018-05-14 2025-12-10 Bruker Spatial Biology, Inc. Verfahren zur erkennung einer zuvor bestimmten nukleotidesequenz
JP7334468B2 (ja) * 2018-05-29 2023-08-29 東ソー株式会社 血液試料保存剤
JP7036670B2 (ja) 2018-05-31 2022-03-15 アークレイ株式会社 血液中の稀少細胞検査、該検査ための血液処理方法及び採血管
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
CN108865976B (zh) * 2018-07-19 2022-06-28 复旦大学附属中山医院 一种离散汲取收集外泌体(exosome)的方法及试剂
CN110250159A (zh) * 2019-05-28 2019-09-20 天津中科生物科技有限公司 一种细胞保护液及其制备方法和应用
US12305235B2 (en) 2019-06-06 2025-05-20 Natera, Inc. Methods for detecting immune cell DNA and monitoring immune system
KR20240168912A (ko) * 2022-03-25 2024-12-02 세키스이 메디칼 가부시키가이샤 순환 종양 세포 분리 키트, 순환 종양 세포 분리 용기 및 순환 종양 세포의 분리 방법
WO2024238350A1 (en) * 2023-05-12 2024-11-21 The Children's Medical Center Corporation Single-cell regulatory multi-omics with deep mitochondrial mutation profiling (redeem)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4040785A (en) * 1976-10-18 1977-08-09 Technicon Instruments Corporation Lysable blood preservative composition
US4320111A (en) * 1977-06-14 1982-03-16 American Home Products Corporation Immunologic compositions methods of preparation and use
FR2475737A1 (fr) * 1980-02-07 1981-08-14 Pasteur Institut Perfectionnements apportes aux procedes de conservation d'hematies par lyophilisation en vue de leur utilisation dans des reactions d'hemagglutination et hematies non agglutinables spontanement obtenues par ce procede
US4404181A (en) * 1981-10-15 1983-09-13 Cambridge Chemical Products, Inc. Extended-life tissue fixative composition and method of using the same
FR2523810B1 (fr) * 1982-03-23 1988-11-25 Carpentier Alain Tissu biologique greffable et procede pour sa preparation
FR2528848A1 (fr) * 1982-06-16 1983-12-23 Sanofi Sa Nouveau derive de thieno-pyridone, son procede de preparation et son application therapeutique
EP0156537A3 (de) * 1984-03-02 1987-05-13 Board Of Regents University Of Texas System Biologische magnetische Flüssigkeiten
US4654312A (en) * 1984-05-14 1987-03-31 Becton, Dickinson And Company Lysing agent for analysis of peripheral blood cells
US4788139A (en) * 1987-08-06 1988-11-29 Streck Laboratories, Inc. Platelet aggregation reagent, reagent container and method of determining platelet aggregation in EDTA-anticoagulated blood
US5385707A (en) * 1988-12-28 1995-01-31 Stefan Miltenyi Metal matrices for use in high gradient magnetic separation of biological materials and method for coating the same
US5698271A (en) * 1989-08-22 1997-12-16 Immunivest Corporation Methods for the manufacture of magnetically responsive particles
US5849517A (en) * 1991-05-08 1998-12-15 Streck Laboratories, Inc. Method and composition for preserving antigens and nucleic acids and process for utilizing cytological material produced by same
EP0627879A1 (de) * 1991-09-20 1994-12-14 CAMIENER, Gerald, W. Verfahren und zusammensetzungen mit einer aldehydstabilisierenden lösung
WO1994018828A1 (en) * 1993-02-25 1994-09-01 Abbott Laboratories Multipurpose reagent system for rapid lysis of whole blood samples
US6190870B1 (en) * 1995-08-28 2001-02-20 Amcell Corporation Efficient enrichment and detection of disseminated tumor cells
GB2313288B (en) * 1996-05-24 2000-07-12 North Gen Hospital Nhs Trust Specimen collection fluid
US6197523B1 (en) * 1997-11-24 2001-03-06 Robert A. Levine Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood
US6670197B2 (en) * 1997-11-24 2003-12-30 David L. Rimm Method for assaying whole blood for the presence or absence of circulating cancer or other target cell fragments
BR9907852A (pt) * 1998-02-12 2000-10-24 Immunivest Corp Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes
WO2000047998A1 (en) * 1999-02-10 2000-08-17 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
EP1221053A4 (de) * 1999-09-13 2004-12-22 Neil H Bander Verfahren zur isolierung von prostatischen epithelzellen aus sperma
CA2457891C (en) * 2001-08-23 2019-10-01 Immunivest Corporation Method of preservation of circulating tumor cells

Also Published As

Publication number Publication date
CA2457894C (en) 2014-07-08
CA2457891A1 (en) 2003-03-06
IL160210A0 (en) 2004-07-25
ATE401574T1 (de) 2008-08-15
CA2457894A1 (en) 2003-03-06
AU2008288601B2 (en) 2012-05-31
CA2457891C (en) 2019-10-01
WO2003019141A2 (en) 2003-03-06
KR20040053115A (ko) 2004-06-23
EP1425383A4 (de) 2005-11-09
WO2003018757A2 (en) 2003-03-06
WO2003018757A3 (en) 2003-09-12
IL160209A0 (en) 2004-07-25
JP2005502863A (ja) 2005-01-27
EP1425294A4 (de) 2005-11-16
KR20040030984A (ko) 2004-04-09
JP2009109514A (ja) 2009-05-21
JP2005501236A (ja) 2005-01-13
AU2009200013B2 (en) 2012-03-08
DE60227678D1 (de) 2008-08-28
EP1425383A2 (de) 2004-06-09
WO2003019141A3 (en) 2004-04-01
CN1596265A (zh) 2005-03-16
BR0212125A (pt) 2005-06-28
EP1425294B1 (de) 2008-07-16
BR0212124A (pt) 2004-07-20
AU2008288601A1 (en) 2009-04-02
CN1571634A (zh) 2005-01-26
EP1425294A2 (de) 2004-06-09
AU2009200013A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
EP1425294B2 (de) Analyse zirkulierender tumorzellen, fragmente und trümmer
US7863012B2 (en) Analysis of circulating tumor cells, fragments, and debris
EP2628008B1 (de) Verfahren und kits für den nachweis von zirkulierenden tumorzellen bei pankreastumorpatienten mittels polyspezifischer capture- und cocktailnachweisreagenzien
AU2008249153B2 (en) Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US7901950B2 (en) Method for assessing disease states by profile analysis of isolated circulating endothelial cells
WO2006054991A1 (en) Magnetic enrichment of circulating cells, fragments and debris for enabling hts proteomics and genomics in disease detection
ES2357101T3 (es) Celulas marcadas para su uso como control funcional interno en ensayos de detección de celulas raras.
US20090191535A1 (en) Method of assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
JP5548890B2 (ja) 細胞の画像を格付けするための方法
EP1861509A2 (de) Verfahren zur vorhersage des überlebens insgesamt und ohne krankheitsfortschreitung zu jedem nachsorgezeitpunkt bei der therapie von metastatischen brustkrebspatienten unter verwendung zirkulierender tumorzellen
WO2006041453A1 (en) Circulating tumor cells (ctc’s): apoptotic assessment in prostate cancer patients
Rao et al. Analysis of circulating tumor cells, fragments, and debris
AU2002326741A1 (en) Analysis of circulating tumor cells, fragments, and debris
WO2006020936A2 (en) A method for assessing disease states by profile analysis of isolated circulating endothelial cells
WO2006130737A1 (en) A method for assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040315

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 5/16 B

Ipc: 7C 12N 5/00 B

Ipc: 7C 07K 1/00 A

Ipc: 7C 07K 17/00 B

Ipc: 7G 01N 33/53 B

Ipc: 7C 12N 1/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20051006

RIC1 Information provided on ipc code assigned before grant

Ipc: 7G 01N 33/543 A

Ipc: 7G 01N 33/569 B

17Q First examination report despatched

Effective date: 20060301

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 60227678

Country of ref document: DE

Date of ref document: 20080828

Kind code of ref document: P

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20080918

Year of fee payment: 7

Ref country code: DK

Payment date: 20080901

Year of fee payment: 7

Ref country code: ES

Payment date: 20080829

Year of fee payment: 7

Ref country code: LU

Payment date: 20080902

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20080829

Year of fee payment: 7

Ref country code: IE

Payment date: 20080902

Year of fee payment: 7

Ref country code: MC

Payment date: 20080829

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081216

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081016

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080716

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080716

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080716

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080716

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080716

26 Opposition filed

Opponent name: STRECK INC.

Effective date: 20090415

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080716

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080716

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: STRECK INC.

Effective date: 20090415

NLR1 Nl: opposition has been filed with the epo

Opponent name: STRECK INC.

NLR1 Nl: opposition has been filed with the epo

Opponent name: STRECK INC.

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: VERIDEX, LLC

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081016

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: VERIDEX, LLC

Effective date: 20091223

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20100506 AND 20100512

REG Reference to a national code

Ref country code: NL

Ref legal event code: SD

Effective date: 20100518

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080716

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090824

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080716

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090823

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20121212

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 60227678

Country of ref document: DE

Effective date: 20121212

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20190827

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20190827

Year of fee payment: 18

Ref country code: FR

Payment date: 20190830

Year of fee payment: 18

Ref country code: IT

Payment date: 20190823

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20190830

Year of fee payment: 18

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60227678

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20200901

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210302

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200831

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200901